Glostrup University Hospital, Copenhagen

rigshospitalet.dk

Total trials

106

Active

5

Phase 3

3

Total enrollment

105,290

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 1 of 1 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Oral semaglutide1

Next readouts

  • 2028-08

Top conditions

  • Type 2 Diabetes5
  • Rheumatoid Arthritis4
  • Healthy4
  • Cardiovascular Disease4
  • Diabetes Mellitus3
  • Pain, Postoperative3
  • Epiretinal Membrane3
  • Diabetic Retinopathy3

Frequently asked questions about Glostrup University Hospital, Copenhagen

How many clinical trials does Glostrup University Hospital, Copenhagen have on ClinicalTrials.gov?
Glostrup University Hospital, Copenhagen is listed as the lead sponsor on 106 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
How many of Glostrup University Hospital, Copenhagen's trials are in Phase 3?
3 of Glostrup University Hospital, Copenhagen's trials are in Phase 3, spread across 1 active drug program.
What therapeutic areas does Glostrup University Hospital, Copenhagen focus on?
Glostrup University Hospital, Copenhagen's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Rheumatoid Arthritis, Healthy, Cardiovascular Disease, Diabetes Mellitus.
When are Glostrup University Hospital, Copenhagen's next clinical trial readouts?
Glostrup University Hospital, Copenhagen has 1 upcoming primary-completion readout tracked here; the soonest is “A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma”, expected around 2028-08.